Solventum Corporation SOLV
NYSE · United States · Health Services
$88.15-1.17 (-1.31%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Despite lagging behind other healthcare stocks over the past year, analysts remain fairly optimistic about Solventum, supported by the stock's bullish momentum and rosy outlook.
The global ostomy dressings market is projected to grow from USD 3.80 billion in 2026 to USD 4.73 billion by 2031, at a 4.4% CAGR. Growth is driven by rising colorectal cancer and inflammatory bowel disease cases, aging populations, improved peristomal skin care awareness, and expanding home care services. Skin barrier rings will record the fastest product growth, while Asia Pacific will be the fastest-growing region. Key companies include Coloplast, ConvaTec, Hollister, B. Braun, Solventum, and
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.